HumacyteHUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Employees: 220
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
33% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 39
13% more funds holding
Funds holding: 143 [Q3] → 162 (+19) [Q4]
9% more capital invested
Capital invested by funds: $195M [Q3] → $213M (+$18M) [Q4]
2.76% more ownership
Funds ownership: 29.94% [Q3] → 32.71% (+2.76%) [Q4]
44% less call options, than puts
Call options by funds: $4.41M | Put options by funds: $7.9M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
D. Boral Capital Jason Kolbert 19% 1-year accuracy 67 / 357 met price target | 1,624%upside $25 | Buy Maintained | 31 Mar 2025 |
HC Wainwright & Co. Vernon Bernardino 18% 1-year accuracy 13 / 71 met price target | 934%upside $15 | Buy Reiterated | 12 Mar 2025 |
Financial journalist opinion
Based on 8 articles about HUMA published over the past 30 days









